531 related articles for article (PubMed ID: 19808839)
1. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
2. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yonese J; Fukui I
Int J Urol; 2008 Jun; 15(6):546-7. PubMed ID: 18489646
[TBL] [Abstract][Full Text] [Related]
3. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
6. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Saad F; Eastham JA
Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.
Montella L; Addeo R; Palmieri G; Caraglia M; Cennamo G; Vincenzi B; Guarrasi R; Mamone R; Faiola V; Frega N; Capasso E; Maiorino L; Leopardo D; Pizza C; Montesarchio V; Del Prete S
Cancer Chemother Pharmacol; 2010 May; 65(6):1137-43. PubMed ID: 19760218
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
Smith MR
Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
[TBL] [Abstract][Full Text] [Related]
13. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
14. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
16. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Mahtani R; Khan R; Jahanzeb M
Clin Lung Cancer; 2011 Jan; 12(1):26-32. PubMed ID: 21273176
[TBL] [Abstract][Full Text] [Related]
17. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Calderone R; Nimako K; Leary A; Popat S; O'Brien ME
Eur J Cancer; 2011 Jul; 47(11):1603-5. PubMed ID: 21684152
[TBL] [Abstract][Full Text] [Related]
18. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
20. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]